“The vaccine they are testing seems to be generally well tolerated and results in roughly effective antibody levels in these volunteers. ”
Madden added that the company is focused on improving the effectiveness of this drug.
“This vaccine uses a new technology called MRNA and if you inject it into the body, it would break down quickly. Acuitas provides delivery technology that protects mRNA after delivery, and then transports it to cells. ”
Madden and her team of 25 are working with BioNTech to make sure the vaccine works once it is injected and there is hope that it will be available early next year.
“The general expectation is that a vaccine may become available in early 2021,” he said.
“We are very fortunate that a fairly large number of different candidate vaccines are under development. We hope that as many of them as possible will succeed. ”
He says the main challenges are that once a vaccine is ready, it makes sure it is safe, and then is able to do it quickly enough to make it available globally.